The LATTE study: a provocative brew

Affiliations

¹ The Kirby Institute for Infection and Immunity in Society, UNSW Australia, Sydney, NSW 2052, Australia. Electronic address: mboyd@kirby.unsw.edu.au.
² The Kirby Institute for Infection and Immunity in Society, UNSW Australia, Sydney, NSW 2052, Australia.

Comment

Mark Alastair Boyd et al. Lancet Infect Dis. 2015 Oct.

. 2015 Oct;15(10):1116-1117.

doi: 10.1016/S1473-3099(15)00224-8. Epub 2015 Jul 19.

¹ The Kirby Institute for Infection and Immunity in Society, UNSW Australia, Sydney, NSW 2052, Australia. Electronic address: mboyd@kirby.unsw.edu.au.
² The Kirby Institute for Infection and Immunity in Society, UNSW Australia, Sydney, NSW 2052, Australia.

No abstract available

Comment on

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
Margolis DA, Brinson CC, Smith GHR, de Vente J, Hagins DP, Eron JJ, Griffith SK, Clair MHS, Stevens MC, Williams PE, Ford SL, Stancil BS, Bomar MM, Hudson KJ, Smith KY, Spreen WR; LAI116482 Study Team. Margolis DA, et al. Lancet Infect Dis. 2015 Oct;15(10):1145-1155. doi: 10.1016/S1473-3099(15)00152-8. Epub 2015 Jul 19. Lancet Infect Dis. 2015. PMID: 26201299 Clinical Trial.